Since PARP inhibitors are blocking the pathway to repair damaged DNA; they require a selective increase in DNA damage to tumor cells compared to normal cells in order to produce an enhanced therapeutic effect by chemotherapy. The gene discussed is PARP1; the disease is neoplasm.